The present patent document describes methods for enhancing the aesthetic appearance of a human face by injecting soft tissue filler material in the temporal region. The soft tissue filler material is injected into a subdermal plane; preferably from an injection site about 1 cm anterior to the apex of the tragus. A single injection may be performed on either side of the face.

The particle (1) is suitable for the manufacture of an implantable soft tissue engineering material and comprises: a three-dimensionally warped and branched sheet (2) where (i) the three-dimensionally warped and branched sheet (2) is made from a biocompatible material having a Young's modulus of 1 kPa to 1 GPa; (ii) the three-dimensionally warped and branched sheet (2) has an irregular shape which is encompassed in a virtual three-dimensional envelope (3) having a volume V.sub.E; (iii) the three-dimensionally warped and branched sheet (2) has a mean sheet thickness T; iv) the three-dimensionally warped and branched sheet (2) has a volume V.sub.S; (v) the particle (1) has a Young's modulus of 100 Pa to 15 kPa; and (vi) the particle (1) further comprises a number of protrusions where the three-dimensionally warped and branched sheet (2) reaches the envelope (3); (vii) the particle (1) has a number of interconnected channel-type conduits (5) defined by the branching of the sheet (2) and/or by voids in the sheet (2); and (viii) where the conduits (5) have (a) a mean diameter D.sub.C; and (b) an anisotropicity index of 1.01 to 5.00.

A controlled-viscosity polymeric hydrogel including an aqueous solvent, a water-soluble synthetic polymeric component and an anti-cross-linking component, constituted of a polyphenol, in particular of hydroxytyrosol.

In one aspect, a kit includes a sleeve including an outer lining and an inner lining; a pouch arranged within the sleeve and including one or more polymer sheets, a plurality of channels, and a plurality of vents; and a foam precursor capable of forming a foam within the pouch. In one aspect, a method of stabilizing a body part includes providing a sleeve including an outer lining and an inner lining around a body part; providing a pouch arranged within the sleeve and including one or more polymer sheets, a plurality of channels, and a plurality of vents; providing a foam precursor in the pouch; and forming a foam within the pouch.

Implantable bone compositions are provided. The implantable compositions comprise hydratable bone putties. The hydratable bone putties comprise porous ceramic granules having an average diameter from about 50 μm to 800 μm and the composition has a texture value above about 1000. The porous ceramic granules comprise hydroxyapatite and beta-tricalcium phosphate. The implantable bone compositions further include collagen carriers. In some embodiments, the hydratable bone putty can be hydrated to form a non-settable flowable cohesive cement or gel. Methods of making and using the implantable compositions are also provided.

Provided herein are compositions comprising a composite of peptide amphiphiles and biocompatible particles and methods of use thereof for treatment of bone and/or tissue defects. In particular, compositions comprise a slurry paste of a peptide amphiphile nanofiber solution mixed with solid biocompatible particles, and find use in tissue/bone regeneration, growth factor delivery, and/or cell delivery.

An object of the present invention is to provide a cell population comprising adherent cells having low differentiation capacity derived from a fetal appendage, methods for producing or using the same, and a pharmaceutical composition comprising the cell population, in particular wherein the proportion of CD73- and CD90-positive adherent cells derived from a fetal appendage is 90% or more; and the cell population satisfies a relative expression level of LFA-3 gene to the expression level of SDHA gene of 1.0 or more, in particular wherein the relative expression level of HAPLN1 gene to the expression level of SDHA gene is 4.0 or more and/or the relative expression level of CCND2 gene to the expression level of SDHA gene is 1.5 or less, in particular wherein the proportion of the STRO-1-negative adherent cells derived from a fetal appendage is 95% or more.

The invention relates to a dermal filler composition in the form of a gel, comprising a carrier fluid comprising water and/or a polyalcohol; cross-linked hyaluronic acid; and spherical microparticles of cross-linked hyaluronic acid having an average diameter in the range of 10-200 μm. The filler provides a volumizing effect as well as a biostimulating effect when injected into skin tissue.

Methods and compositions are disclosed for repair of shoulder injuries by employing disaggregated muscle fiber fragments to regenerate functional shoulder muscle tissue. In some embodiments, the fragments retain functional satellite cells but exhibit cell wall rupture and have an average size of less than 150 μm. The methods include the preparation and implantation of compositions by extracting muscle tissue from a donor site, disaggregating muscle fibers from the extracted tissue, and fragmenting disaggregated muscle fibers into fiber fragments that exhibit cell wall rupture and preferably have an average size of less than 150 microns, more preferable less than about 100 microns, while retaining functional satellite cells. Upon injection, e.g., into the supraspinatus or other rotator cuff muscles, the muscle fiber fragment compositions are capable of reconstituting or reconstructing elongated muscle fibers from the fragments and orienting in alignment with native shoulder muscle fibers.

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.